(This is only an advertisement for Information purposes and not a Prospectus announcement.)

KWALITY PHARMACEUTICALS LIMITED

CIN: U24232PB1983PLC005426

Our Company was incorporated as 'Kwality Pharmaceuticals Private Limited' a private limited company under the Companies Act, 1956 pursuant to Certificate of Incorporation dated May 04, 1983 issued by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh. Thereafter, our Company was converted into a public limited company under the Companies Act, 2013 and the name of our Company was changed to its present name 'Kwality Pharmaceuticals Limited' pursuant to fresh certificate of incorporation consequent upon change of name on conversion to public limited company dated December 28, 2015 issued by the Registrar of Companies, Chandigarh. For further details of our Company, please refer to the chapters titled 'General Information' and 'History and Certain Corporate Matters' on page numbers 42 and 120, respectively, of the Prospectus.

Registered Office: Village Nagkalan, Majitha Road, Amritsar, Punjab – 143 601, India.
Tel: +91-0183-2774321-25; **Fax:** +91-0183-2774477; **Email:** cs@kwalitypharma.com; **Website:** www.kwalitypharma.com
Company Secretary and Compliance Officer: Ms. Pallavi Agarwal

THE OFFER

PUBLIC OFFER OF 13,80,000 EQUITY SHARES OF FACE VALUE OF ₹ 10.00 EACH OF KWALITY PHARMACEUTICALS LIMITED ("THE COMPANY" OR "KPL") FOR CASH AT A PRICE OF ₹ 45.00 PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ 35.00 PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING TO ₹ 621.00 LAKHS ("THE OFFER") CONSISTING OF A FRESH ISSUE OF 1,80,000 EQUITY SHARES AGGREGATING TO ₹ 81.00 LAKHS (THE "FRESH ISSUE") AND AN OFFER FOR SALE OF 12,00,000 EQUITY SHARES BY SELLING SHAREHOLDER AGGREGATING TO ₹ 540.00 LAKHS ("OFFER FOR SALE")OF WHICH, 72,000 EQUITY SHARES AGGREGATING TO ₹ 32.40 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION I.E. OFFER OF 13,08,000 EQUITY SHARES OF FACE VALUE OF ₹ 10.00 EACH AT AN OFFER PRICE OF ₹ 45.00 PER EQUITY SHARE AGGREGATING TO ₹ 588.60 LAKHS IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE 26.60% AND 25.21%, RESPECTIVELY OF THE POST OFFER PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY

THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10 EACH AND THE OFFER PRICE OF ₹ 45.00 IS 4.5 TIMES OF THE FACE VALUE.

THE APPLICATION MUST BE FOR A MINIMUM OF 3,000 EQUITY SHARES AND IN MULTIPLES OF 3,000 EQUITY SHARES THEREAFTER.

THIS OFFER IS BEING MADE IN TERMS OF CHAPTER XB OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2009 (THE "SEBI (ICDR) REGULATIONS"), AS AMENDED. THIS OFFER IS A FIXED PRICE OFFER AND ALLOCATION IN THE NET OFFER TO THE PUBLIC WILL BE MADE IN TERMS OF REGULATION 43(4) OF THE SEBI (ICDR) REGULATIONS, AS AMENDED. FOR FURTHER DETAILS, PLEASE REFER TO SECTION TITLED "OFFER PROCEDURE" ON PAGE 259 OF THE PROSPECTUS.

PROMOTER OF THE COMPANY – MR. RAMESH ARORA, MR. AJAY ARORA

ASBA*

Simple, Safe, Smart way of Application - Make use of it !!!
*Applications Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For further details, check section on ASBA below.
MANDATORY IN PUBLIC ISSUES FROM JANUARY 01, 2016. NO CHEQUES WILL BE ACCEPTED.

APPLICATIONS SUPPORTED BY BLOCKED AMOUNT (ASBA): All Investors in this Offer have to compulsorily apply through the ASBA process. The investors are required to fill the ASBA form and submit the same to their banks. The SCSB will block the amount in the account as per the authority contained in ASBA form. On allotment, amount will be unblocked and account will be debited only to the extent required to be paid for allotment of shares. Hence, there will be no need of refund.

CORRIGENDUM – NOTICE TO INVESTORS

This is with reference to the Prospectus dated June 20, 2016 ("Prospectus") filed with Registrar of Companies, Punjab Himachal Pradesh and Chandigarh, the Securities and Exchange Board of India ("SEBI") and BSE Limited and the Abridged Prospectus issued in relation to the Offer. All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Prospectus.

Investors should note that, the name referred Arti Seth or Aarti Seth forming part of Promoter Group should be read as Aarti Bajaj and the name referred Pooja Arora forming part of Promoter Group should be read as Pooja Kapoor, wherever appearing in the Prospectus. The change in the names is due to change in their marital status.

For Kwality Pharmaceuticals Limited
On behalf of the Board of Directors
Sd/-
Managing Director

Place : Amritsar, Punjab
Date : June 29, 2016

Kwality Pharmaceuticals Limited is proposing, subject to market conditions and other considerations, a public Offer of its Equity Shares and has filed the Prospectus with the Registrar of Companies Punjab, Himachal Pradesh and Chandigarh. The Prospectus is available on the website of the SEBI at www.sebi.gov.in, the website of the Lead Manager at www.16anna.com, website of the BSE at www.bseindia.com and website of company at www.kwalitypharma.com. Investor should note that investment in equity shares involves a high degree of risk. For details, investors should refer to and rely on the Prospectus, including the section titled "Risk Factors" beginning on page 13 of the Prospectus, which has been filed with ROC. This announcement has been prepared for publication in India and may not be released in the United States. This announcement is not an Offer to sell or solicitation of any offer to buy securities of our Company in the United States. The Equity Shares have not been and will not be registered under the US Securities Act ("the Securities Act") or any state securities laws in the United States. The Equity Shares have not been and will not be registered under Securities Act or any state securities laws under United States, and unless so registered, may not be offered or sold within the United States except pursuant an exemption from or in the transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws.

Accordingly, such Equity Shares are being offered and sold outside the United States in offshore transactions in Reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur.

Baki